相关实验视频
Updated: Jun 9, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
434
在阿尔茨海默病试验中评估临床进展措施:系统性审查和元分析
Jonathan McLaughlin1, William J Scotton2, Natalie S Ryan2,3
1University of Aberdeen, NRS Career Researcher Fellow, Royal Cornhill Hospital, Scotland, UK.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 23, 2024
概括
功能性测量,如功能性活动问卷 (FAQ),在临床试验中对跟踪阿尔茨海默病 (AD) 进展最为敏感. 仅仅是认知措施对早期AD检测效果不那么好.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 生物标志物 生物标志物
背景情况:
- 可靠的结果测量对于评估阿尔茨海默病 (AD) 治疗和进展至关重要.
- 本研究的重点是针对已确认粉样β (Aβ+) 状态的AD患者的随机对照试验 (RCT) 中临床进展指标的敏感性.
研究的目的:
- 评估和比较AD临床试验中使用的各种临床进展措施的敏感性.
- 确定跟踪AD进展的最有效措施,特别是在早期和临床前阶段.
主要方法:
- 25个选定的RCT的元分析,不包括对非认知症状的试验.
- 使用了R版本4.2.0以及用于数据分析的metafor和emmeans库.
主要成果:
- 功能活动问卷 (FAQ) 在12周内显示出最高的灵敏度.
- 综合评分 (iADRS,CDR-SB) 比单个认知组件更敏感;神经精神病学测量是最不敏感的.
- 在检测AD进展方面,功能性测量通常优于仅认知性测量.
结论:
- 功能性测量优于仅用于追踪早期AD进展的认知性测量.
- 目前的结果测量对早期和临床前AD阶段的敏感性有局限性.
- 未来的AD进展措施应整合认知和功能组件,以提高敏感性.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.6K
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
19.6K
相关概念视频
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165